Rockland Trust Co. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 97.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,795 shares of the biopharmaceutical company’s stock after selling 173,450 shares during the quarter. Rockland Trust Co.’s holdings in Gilead Sciences were worth $339,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Waldron LP grew its position in shares of Gilead Sciences by 20.4% during the first quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after purchasing an additional 1,752 shares in the last quarter. Hikari Power Ltd grew its position in shares of Gilead Sciences by 32.6% during the first quarter. Hikari Power Ltd now owns 51,700 shares of the biopharmaceutical company’s stock worth $3,511,000 after purchasing an additional 12,700 shares in the last quarter. Physicians Financial Services Inc. grew its position in shares of Gilead Sciences by 34.2% during the first quarter. Physicians Financial Services Inc. now owns 15,590 shares of the biopharmaceutical company’s stock worth $1,059,000 after purchasing an additional 3,975 shares in the last quarter. Narwhal Capital Management grew its position in shares of Gilead Sciences by 17.0% during the first quarter. Narwhal Capital Management now owns 30,655 shares of the biopharmaceutical company’s stock worth $2,082,000 after purchasing an additional 4,465 shares in the last quarter. Finally, Stonebridge Capital Management Inc. grew its position in shares of Gilead Sciences by 11.7% during the first quarter. Stonebridge Capital Management Inc. now owns 61,680 shares of the biopharmaceutical company’s stock worth $4,189,000 after purchasing an additional 6,450 shares in the last quarter. 73.98% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at $242,749,648.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Insiders sold 486,819 shares of company stock valued at $39,298,919 over the last 90 days. Company insiders own 1.30% of the company’s stock.

Gilead Sciences, Inc. (GILD) opened at 82.14 on Monday. The stock has a market cap of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14. The stock has a 50 day moving average price of $80.97 and a 200-day moving average price of $71.66. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business’s revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.08 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/09/rockland-trust-co-sells-173450-shares-of-gilead-sciences-inc-gild.html.

GILD has been the subject of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price for the company in a research report on Wednesday, September 6th. Morgan Stanley reiterated an “equal weight” rating and set a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, ValuEngine cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $85.66.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.